The safety, kinetics and efficacy of plerixafor+pegfilgrastim for hematopoietic stem and progenitor cell (HSPC) mobilization are poorly understood. We treated 12 study patients (SP; lymphoma n = 10 or myeloma n = 2) with pegfilgrastim (6 mg SC stat D1) and plerixafor (0.24 mg/kg SC nocte from D3). Six SP were 'predicted poor-mobilizers' and six were 'predicted adequate-mobilizers'. Peripheral blood (PB) CD34 + monitoring commenced on D3. Apheresis commenced on D4. Comparison was with 22 historical controls (HC; lymphoma n = 18, myeloma n = 4; poor mobilizers n = 4), mobilized with pegfilgrastim alone. Eight (67%) SP had PB CD34 + count ⩽ 5 × 10 6 /L D3 post pegfilgrastim; all SP surpassed this threshold the morning after plerixafor. In SP, PBCD34 + counts peaked D4 6/12 (50%), remaining ⩾ 5 × 10 6 /L for 4 days in 8/12 (67%). All SP successfully yielded target cell numbers (⩾2 × 10 6 /kg) within four aphereses. After maximum four aphereses, median total CD34+ yield was higher in SP than HC; 8.0 (range 2.4-12.9) vs 4.8 (0.4-14.0) × 10 6 /kg (P = 0.04). Seven of twelve (58%) SP achieved target yield after one apheresis. Flow cytometry revealed no tumor cells in PB or apheresis product of SP. Plerixafor+pegfilgrastim was well tolerated with bone pain (n = 2), diarrhoea (n = 2) and facial paraesthesiae (n = 3). Plerixafor+pegfilgrastim is a simple, safe and effective HSPC mobilization regimen in myeloma and lymphoma, in both poor and good mobilizers, and is superior to pegfilgrastim alone.
INTRODUCTION
The use of mobilized peripheral blood (PB) hematopoietic stem and progenitor cells (HSPCs) for hematopoietic SCT has produced improved transplant outcomes compared with BM-derived cells, with improved platelet engraftment and survival rates post transplant.
1,2 G-CSF is the mainstay of HSPC mobilization, either as a single agent or following chemotherapy. In autologous SCT, approximately 10-20% of patients, and up to 60% of those exposed to stem cell toxic therapies such as fludarabine, may fail to yield adequate numbers of HSPC. [3] [4] [5] Novel agents are sought to improve mobilization efficiency by minimizing the number of apheresis days, increase cell yields and reduce the mobilization failure rate in difficult-to-mobilize patients.
Improved understanding of the molecular aspects of HSPC homing to the BM niche has led to the development of novel agents designed to disrupt the bonds between these cells and their microenvironment. Plerixafor (AMD300, Mozobil, Wiltshire, UK) is a novel chemokine receptor 4 (CXCR4) antagonist which disrupts the CXCR4/SDF-1α bond, inducing prompt mobilization of HSPC into the circulation. 6 This agent has proven effective at HSPC mobilization as a single agent, and shows particular synergy when combined with G-CSF. 7 When combined with G-CSF (typically at doses of 10 μg/kg daily, starting 3-4 days before the addition of plerixafor), nightly plerixafor injections at doses of 240 μg/kg can increase the PB CD34+ cell count by approximately two to threefold, 8, 9 and the combination 'plerixafor plus G-CSF' protocols show superior mobilization kinetics and yields compared with G-CSF alone. 10 Plerixafor has achieved Food and Drug Administration approval, and in combination with G-CSF is indicated for HSPC mobilization in patients with lymphoma and multiple myeloma. 11, 12 Engraftment of HSPC mobilized using plerixafor plus G-CSF is comparable with engraftment of HSPC mobilized with G-CSF alone. 11, 12 Interestingly, there is emerging data indicating that plerixafor may mobilize HSPC with a slightly different phenotype. Plerixafor-mobilized HSPC grafts are higher in CD3+ T cells, interferon-γ and tumur necrosis factor-α-secreting CD8+ T cells and plasmacytoid dendritic cells, with functional differences also noted in the regulatory T-cell content of these grafts. 13 The clinical significance of these differences remains to be determined, but could represent a useful adjunct to the immunotherapy component of HSPC transplantation.
Pegylated G-CSF (pegfilgrastim) has a prolonged half-life compared with the native molecule (33 vs 3-4 h), 14 and is indicated for prevention of neutropenia after chemotherapy. A single injection of 6 or 12 mg also induces effective HSPC mobilization as a cytokine-alone regimen (without chemotherapy) 15, 16 as seen in healthy volunteers, 17 healthy allogeneic donors 18 and patients with myeloma. 19 Recently, we demonstrated that pegfilgrastim alone as a mobilization strategy has similar mobilization efficacy to multiple daily doses of filgrastim 20 ; however, there is little published data on the combination of pegfilgrastim and plerixafor as a cytokine-only regimen for HSPC mobilization. The combination of plerixafor and pegfilgrastim has appeal due to its ease of administration, likely increased acceptability to patients and its capacity to be an entirely outpatient-based regimen.
We hypothesized that plerixafor plus pegfilgrastim would be safe, feasible and produce brisk mobilization kinetics even in anticipated poor mobilizers. We designed a prospective phase I clinical trial evaluating plerixafor plus pegfilgrastim mobilization of PBSC in a cohort of anticipated poor-mobilizer and predicted adequate-mobilizer patients with lymphoma or myeloma. We then compared overall results of this study with a group of historical controls (HC) mobilized with pegfilgrastim alone.
MATERIALS AND METHODS

Eligibility criteria
Patients deemed suitable for cytokine-alone mobilization were screened for eligibility for this study. Inclusion criteria mandated age between 16-70 years, histologically proven multiple myeloma or lymphoproliferative disease, an absolute neutrophil count between 1.5 and 10.0 × 10 9 /L at baseline, adequate renal function: creatinine clearance (estimated glomerular filtration rate of ⩾ 30 mL/min), Eastern Cooperative Oncology Group (ECOG) performance status ⩽ 2, and a life expectancy of at least 2 months. Patients needed to be suitable for home administration of study medications. Patients were excluded if they demonstrated active infection, were pregnant or breast feeding, had significant non-malignant disease including uncontrolled hypertension or unstable angina, known allergy to Escherichia coli-derived products.
In addition, recruitment was prospectively stratified to include six patients predicted to be 'adequate mobilizers', defined as the absence of all the following risk factors for poor mobilization: (1) prior failed attempt at mobilization, (2) prior exposure to fludarabine, (3) prior exposure to more than three regimens of alkylating chemotherapy, (4) prior exposure to irradiation of sternum, pelvis, axial skeleton or femora or (5) prior treatment with more than three lines of conventional chemotherapy (not including biological agents such as single agent rituximab, thalidomide, lenalidomide or bortezomib). Six patients defined as predicted poor mobilizers were included on the basis of the presence of one or more of the previous five risk factors.
Mobilization regimen: study group Twelve patients with lymphoma (n = 10) or myeloma (n = 2) were mobilized using the following outpatient-based, self-administered regimen ( Figure 1 ): Pegfilgrastim 6 mg SC mane was administered as a single dose on day 1 (D1). PB CD34 + (PBCD34 + ) cell monitoring commenced on D3 (to observe the effects of pegfilgrastim alone). Apheresis did not commence until D4. Plerixafor (0.24 mg/kg SC) was administered at 2200-2300 hours each night from D3, for a maximum of four doses. Apheresis commenced 0800 hours daily from D4 (regardless of PBCD34+ cell count) and continued for a maximum four procedures. A successful CD34+ cell yield was defined as a ⩾ 2 × 10 6 /kg and an optimum of 5 × 10 6 /kg, within a maximum of four apheresis procedures.
Mobilization regimen: HC Twenty-two patients with lymphoma (n = 18) or myeloma (n = 4) were mobilized using the following outpatient-based, self-administered regimen ( Figure 1 ): Pegfilgrastim, initially 12 mg (n = 20) and subsequently 6 mg (n = 2) SC mane, was administered as a single dose, D1. The dose of pegfilgrastim was reduced to 6 mg after data was published demonstrating equivalent efficacy. 16 PB CD34+ cell monitoring commenced on D4 and apheresis commenced when PBCD34+ cell count reached >5 × 10 6 /L. Apheresis continued daily until maximum four procedures or until target CD34+ cell yield was reached.
Apheresis
Autologous HPC-A collections were performed by the apheresis unit under cGMP conditions using Cobe Spectra (Cobe, Denver, CO, USA) and Haemonetics MCS+ (Baxter Healthcare Corp, Deerfield, IL, USA ) apheresis machines. Collection was performed according to local institutional practice, namely until two blood volumes (spectra-continuous processing) or 1.5 blood volumes (MCS+-discontinuous processing) were processed.
Flow cytometric CD34+ cell HPC determination CD34+ cell counts were performed using a single platform method based on the ISHAGE gating strategy using a flow cytometer (Becton Dickinson FACSCalibur San Jose, CA, USA). Briefly, a volume of whole blood or buffy coat was incubated with 10 μL of CD45 FITC (Immunotech clone J33, Marseille, France), 10 μL of CD34 PE (Immunotech clone 581, Marseille, France) and 10 μL of 7AAD for 15 min at room temperature in the dark. Red cells were then lysed with ammonium chloride for 10 min. An equal volume of well-mixed FlowCount fluorospheres of known concentration was then added and data acquired on the flow cytometer without washing. PB CD34+ cell count results and collection of CD34+ cell yield results were calculated and reported as cells × 10 6 /L and cells × 10 6 /kg body weight, respectively.
Minimal residual disease by flow cytometry All minimal residual disease immunophenotyping was performed on a FACS Canto T II, (BD Biosciences, San Jose, CA, USA). A target of 500 000 events was acquired in a one-tube, eight-colour lymphoma panel containing the following antibody combination: CD45-Pacific Orange, CD19-V450, lambda-PE, kappa-FITC, CD10-PE-Cy7, CD5-PerCPCy5.5, CD22-APC and CD20-APC-H7. All antibodies were obtained from Becton Dickinson (San Jose, CA, USA) or Beckman-Coulter (Fullerton, CA, USA). Minimal residual disease was defined as a well clustered, clonal population, identified through sequential-gating strategies, including CD19 vs SSc. The two-tube myeloma panel comprised the following antibody combination as a backbone: CD38-V450, CD3-V500, CD19-PE-Cy7, CD138-APC and CD45-APC-H7 with cytoplasmic Kappa-FITC, cytoplasmic Lambda-PE and CD117-PerCP-Cy5.5 in one tube, and CD81-FITC, CD27-PE and CD28-PerCP-Cy5.5 in the second. Minimal residual disease for plasma cells was defined as a well-clustered population with aberrancy as defined by Rawstron et al. 21 Sequential gating strategies used CD38, 138 and physical cell characteristics to define the plasma cells.
Statistical methods
For comparison between the study group and HC, the two-sided Fishers' exact test was used for categorical variables, the exact Cochran-Armitage test for ordinal categorical variables and the Mann-Whitney and t-tests for continuous variables. Continuous variables that were not normally distributed were transformed on a natural log scale to assess differences between groups. Successful mobilization was defined as collection of ⩾ 2 × 10 6 CD34+ cells per kg. The 95% confidence interval for the percentage of patients with successful collection was calculated using an exact method based on the binomial distribution (Blyth-Still-Casella method). A log-rank (Mantel-Cox) test was used to assess time to achieving the target collection yield.
RESULTS AND DISCUSSION
Patient characteristics Study patients. Between July 2009 and February 2010, six 'predicted poor-mobilizers' (five prior failed, one fludarabineexposed) and six 'predicted adequate-mobilizers' were mobilized with plerixafor/pegfilgrastim. Poor mobilizers had been exposed to median 3 (range 1-4) prior lines of chemotherapy-containing therapies, compared with median 1 (1-2) prior lines of therapy in the predicted adequate mobilizers. Prior exposure of the red marrow to radiotherapy was not different between the two groups (Tables 1  and 2 ). No study patients (SP) had prior exposure to lenalidomide. The poor mobilizer group had a median of 1 prior mobilization attempt (range 1-4). Three of the poor mobilizers had had one prior successful collection followed by 1-3 subsequent failed collections. Only one of the predicted adequate mobilizer group had had a prior mobilization attempt, which was successful.
HC. Twenty-two patients with lymphoma (n = 18) or myeloma (n = 4) were identified from pharmacy records as having attempted mobilization with pegfilgrastim alone between October 2007 and October 2009. HC were largely well matched to the SP apart from a lower incidence of prior failed mobilization and a lower number of prior lines of chemotherapy in the control group (Tables 1 and 2 ). Accordingly, mobilization efficacy comparisons were performed after correcting for these variables. Four of the twenty-two HC were identified as predicted poor mobilizers using the criteria employed for the SP (see Materials and methods section). No historical control patients had prior exposure to lenalidomide.
Safety and tolerability of Plerixafor plus Pegfilgrastim for HSPC mobilization Within the SP, the combination of plerixafor plus pegfilgrastim was well tolerated: bone pain (worst grade = 3, n = 2), gastrointestinal symptoms (diarrhoea: worst grade = 2, n = 2) and facial paraesthesiae (n = 3) were the most frequent adverse events. Only two SP have currently undergone transplantation, thus engraftment data are currently incomplete.
PBCD34+ cell kinetics SP. Eight of twelve (33%) patients had a PBCD34+ cell count ⩽ 5 × 10 6 /L (our institutional threshold for collection) on D3 post pegfilgrastim, and apheresis did not commence until D4 as per study protocol. Following the D3 evening dose of plerixafor, all patients had surpassed this threshold on the morning of D4 (Figure 2) .
The median fold increase in PBCD34+ cells from D3 to D4 (that is, after the first plerixafor injection) was 7.9 (range 3.9-24.3), with no significant difference between good and poor mobilizers; 7.2 (4.1-9.3)-fold compared with 10.7 (3.9-24.3)-fold, respectively (P = 0.14) (Figure 2 ). PBCD34+ cell counts were sustained above 5 × 10 6 /L for 4 days in 8/12 (67%) patients and 5 days in 4/12 (33%) patients (data not shown).
PB CD34+ cell counts peaked on D4 in 6/12 patients, D5 in 5/12 and D7 in 1/12. Poor mobilizers tended peak later (median day 5, range 4-7), compared with good mobilizers who tended to peak on median day 4 (range 4-5)- (Figure 3 ).
HC. There was no difference in daily PBCD34+ cell counts between the SP and HC (data not shown). Table 3 .
HC. Twenty of twenty-two (91%) controls yielded ⩾ 2 × 10 6 /kg CD34 + cells within a median 3 (1-4) apheresis procedures. When adjusted for the number of prior-failed mobilizers, the cumulative CD34+ cell yield was 2.5 (1.4-2.5) times higher in the study group than historical controls by day 4 of apheresis (P = 0.03) and there was a trend toward the study group having a higher odds ratio for success (⩾2 × 10 6 /kg collection) within a single apheresis than controls (odds ratio (95% confidence interval): 10.1 (1.0-98.2)).
Tumor cell mobilization Day 4 PB as well as apheresis product from each study patient was assayed for the presence of detectable disease by flow cytometry, as an indicator of possible tumor cell mobilization. The median (range) number of total events was 500 000 (173 000-2 270 000). No flow cytometry-detectable disease was demonstrated in the apheresis product of any patients. One patient with Waldenstrom Macroglobulinaemia had immunophenotypic evidence of disease at baseline, with clonal cells demonstrated. This patient did not have sufficient plasma cell events in PB or apheresis product for meaningful analysis despite 150 000 events attained on days 3 and 4.
DISCUSSION AND CONCLUSIONS
This is the first prospective clinical trial reported to show that plerixafor plus pegfilgrastim is a well tolerated and effective HSPC mobilization regimen in myeloma and lymphoma, in both poor and good mobilizers. Adverse events were mild and acceptable, and comparable with published data on the more commonly used plerixafor/filgrastim combination, 22 and all patients self-injected at Table 3 . CD34+ yields and kinetics-study group vs historical controls Plerixafor plus pegfilgrastim patients Pegfilgrastim-alone historical controls
P-value
All (n = 12) Predicted poor mobilizers (n = 6) Predicted adequate mobilizers (n = 6) home without incident. There was a theoretical concern regarding the risk of hyperleukocytosis with pegfilgrastim plus plerixafor, which was not borne out in this study. One historical control patient mobilized with pegfilgrastim alone at our institution 20 had developed hyperleukocytosis after a dose of pegfilgrastim 12 mg for the purposes of cytokine-alone mobilization. Although this case resolved without incident, a dose of pegfilgrastim 6 mg was chosen prospectively for this study and no cases of hyperleukocytosis were observed.
A potential weakness of the historical control comparison in this study is that the majority of the control group was dosed with 12 mg pegfilgrastim rather than 6 mg in the minority. It is noted, however, that the efficacy of both doses is similar in the published data, 15, 16 and that the comparison in this study was therefore valid.
Pegfilgrastim is currently marketed only for prevention of chemotherapy-induced neutropenia; however, published data support its safety and efficacy in HSPC mobilization, either alone or post-chemotherapy. Data from this trial point to the likely safety and efficacy of adding pegfilgrastim and plerixafor to a mobilizing chemotherapy cycle. This could be particularly relevant in anticipated poor mobilizers undergoing mobilizing chemotherapy as part of a salvage regimen for relapsed disease. As seen in studies of plerixafor and filgrastim, 22 mobilization in this study was brisk, with all plerixafor plus pegfilgrastim patients in our study achieving their target yield within four collections; the majority within two collections (even in heavily pre-treated patients). These brisk kinetics have been heralded as a key argument for the judicious use of plerixafor to improve the efficacy of apheresis units. 23 Others using pegfilgrastim for mobilization have observed a 'dip' in CD34+ cell numbers after one or two days' apheresis, often in the context of recovery from myelosuppressive chemotherapy (where increases in circulating neutrophils may 'mop up' pegfilgrastim due to their expression of the G-CSF receptor). 24 Although this can be overcome with the use of 'booster' doses of filgrastim, the sustained increase in PBCD34+ cell counts for 4-5 days seen in this study indicates the possibility that plerixafor may abrogate this effect, as its metabolism is not affected by the presence of circulating neutrophils.
Many centres advocate the risk-adapted use of plerixafor, to minimize the costs of mobilization. In these regimens, the addition of plerixafor is timed to 'rescue' patients whose PBCD34+ counts indicate that they are likely to fail mobilization. 25, 26 Risk-adapted protocols will enable the use of far fewer plerixafor injections than were used in this study. Recent data also suggest that when pegfilgrastim 12 mg stat dose, rather than filgrastim 10 mcg/kg/ day is used for steady-state mobilization in a risk-adapted plerixafor protocol, pegfilgrastim-mobilized patients were less likely to require the addition of plerixafor to meet mobilization targets. 27 Our data would suggest that the cost of mobilization in this protocol could be further reduced by the use of 6 mg pegfilgrastim.
As cytokine-only mobilizations are generally reserved for 'justin-case' collections at our institution, it is not surprising that only two of the twelve SP have undergone transplantation (both for progressive disease) to date. More studies are needed to determine the engraftment kinetics of cells mobilized with plerixafor and pegfilgrastim, especially as plerixafor will, in most institutions, be reserved for patients with poor mobilization. Poor mobilizer patients, including those exposed to fludarabine or >4 cycles of lenalidomide are a group in whom comparatively low collection yields may be obtained, even with plerixafor, and their engraftment may be suboptimal due to a lower cell dose at the time of transplant. 28, 29 Theoretical concerns have been raised regarding possible tumor cell mobilization when using agents that disrupt the CXCR-4/CXCL12 interaction; 30 however, the significance of tumor contamination of apheresis product is controversial and has not been inconclusively linked with the risk of relapse. Indeed, this feature may be used as a possible chemosensitization strategy in certain diseases such as AML. [31] [32] [33] A study of poor mobilizer multiple myeloma patients showed no evidence of tumor contamination in the apheresis product after plerixafor plus filgrastim mobilization. 34 In our study, there were no detectable tumor cells present in the apheresis product on flow cytometry; however, further studies using both flow cytometry and molecular techniques may yield more information on tumor mobilization in various diseases after plerixafor treatment.
In comparison to HC mobilized with pegfilgrastim alone, CD34+ cell kinetics were similar with a trend toward a higher odds ratio for successful mobilization within a single apheresis in the study group. It is likely that this regimen will provide the largest incremental benefit to patients expected to mobilize poorly. 35 We therefore conclude that the combination of plerixafor plus singledose pegfilgrastim is well tolerated, safe and effective for HSPC mobilization in both good and poor mobilizers.
